Ariad Announces Updated Findings from Pivotal Pace Trial of Ponatinib...  - CNBC

This trial is being conducted in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblasatic leukemia (Ph + ALL) who are resistant or intolerant to either nilotinib or dasatinib, two currently available CML ...

Ariad Announces Updated Findings from Pivotal Pace Trial of Ponatinib to Be Presented at Annual Meeting of American Society of Clinical Oncology - Yahoo Finance

This trial is being conducted in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblasatic leukemia (Ph + ALL) who are resistant or intolerant to either nilotinib or dasatinib, two currently available ...

Girl self-diagnoses leukaemia after watching Cameron Diaz film - Daily Telegraph

Medics have now told Alex she is in remission after two years of taking powerful chemotherapy drug Dasatinib - and her condition is now manageable. But amazingly, Alex yesterday admitted she may never have caught the cancer in time if she hadn't sat down ...

Bio-Pharma Catalyst Trades And ASCO Movers: Making The Grade - Seekingalpha.com

Ariad Pharma (ARIA) 5/7/12 pps: $16.09. Market cap: $2.56B ASCO Catalyst trade factor mentioned last week: Phase 2 pivotal data on Ponatinib CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib. The primary target for ponatinib is BCR-ABL ...

Today's Bio-Pharma Catalyst Trades And ASCO Movers - Seekingalpha.com

Ariad Pharma (ARIA) 5/7/12 pps: $16.09. Market cap: $2.56B ASCO Catalyst trade factor: Phase 2 pivotal data on Ponatinib CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib. The primary target for ponatinib is BCR-ABL, an abnormal tyrosine ...

Prostate cancer drug Abiraterone set for approval in England and Wales but not Scotland - Daily Mail

It costs £12,000 a year and is available in Scotland. In May 2011 Nice turned down dasatinib, high-dose imatinib and nilotinib, which can give normal life expectancy for those with a rare blood cancer. The treatment costs £40,000 a year and is available in Scotland.

Increased Mammograms Up to 65% Responsible for Breast Cancer Mortality Reduction - msnbc.com

Dasatinib (Sprycel), Docetaxel (Taxotere), Dovitinib, Doxorubicin liposomal (Doxil), Eribulin (Halaven), Erlotinib (Tarceva), Everolimus (Afinitor), Exemestane (Aromasin), Fadrozole (Afema), Fluoxymesterone, Fulvestrant (Faslodex), Ganitumab ...

New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting - Yahoo Finance

Treatment with SPRYCEL® (dasatinib) can cause severe (NCI CTC Grade 3/4) thrombocytopenia, neutropenia, and anemia, occurring more frequently in advanced phase CML or Ph+ ALL than in chronic phase CML. Myelosuppression was reported in patients ...

Health care - the 2012-13 Budget breakdown - Pharmacy News

and the leukaemia treatments dasatinib and nilotinib. Total cost $72 million over five years. PBS savings worth $104 million would be accrued from price... This site is intended for Registered Medical Practitioners.

Antiretroviral Contraindications and Drug Interactions Chart - Monthly Prescribing Reference

Potentiates fentanyl, parenteral midazolam; monitor. • Potentiates anticancer agents (eg, vincristine, vinblastine, dasatinib, nilotinib); may need dose adjustment (see literature). • Potentiates colchicine; adjust dosing (see literature). Concomitant ...